Sonoma Pharmaceuticals Inc
For the period ended Mar 31, 2024. Filed Jun 17, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Jun 17, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| SONOMA PHARMACEUTICALS, INC. | ||
| Date: June 17, 2024 | By: | /s/ Amy Trombly |
|---|---|---|
| Amy Trombly President and Chief Executive Officer, (Principal Executive Officer) | ||
| Date: June 17, 2024 | /s/ Jerome Dvonch | |
| Jerome Dvonch | ||
| Chief Financial Officer | ||
| (Principal Financial and Principal Accounting Officer | ||
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ Amy Trombly | President, Chief Executive Officer | June 17, 2024 |
| Amy Trombly | (Principal Executive Officer) | |
| /s/ Jerome Dvonch | Chief Financial Officer | June 17, 2024 |
| Jerome Dvonch | (Principal Financial and Principal Accounting Officer) | |
| /s/ Jay Edward Birnbaum | Director | June 17, 2024 |
| Jay Edward Birnbaum | ||
| /s/ Philippe Weigerstorfer | Director | June 17, 2024 |
| Philippe Weigerstorfer | ||
| /s/ Jerry McLaughlin | Director | June 17, 2024 |
| Jerry McLaughlin | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.